Investor relations

press releases

03/16/2023

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

03/14/2023

PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery

02/07/2023

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement

PainReform Provides Business Update for the Third Quarter of 2022

11/08/2022

PainReform Provides Further Update on Manufacturing of PRF-110

10/04/2022

PainReform Provides PRF-110 Manufacturing Update